Redcare Pharmacy stock trades below last year’s highs as analysts lift targets

Redcare Pharmacy (ISIN NL0012044747) stock is currently trading significantly below its highs from the previous year, even as recent analyst target price increases underscore continued confidence in the company’s growth prospects as of August 17, 2026.

Analyst targets signal confidence despite softer share price

Recent coverage of Redcare Pharmacy highlights that the average analyst target price stands at 61.00 EUR, compared with a current market price level reported in the high-50s to low-60s range on European trading venues. An analyst consensus overview shows an average target price of 61.00 EUR alongside individual targets that extend into the low 100 EUR range, indicating that the consensus still expects upside from present levels.

In a detailed German-language analysis of Redcare Pharmacy published August 17, 2026, the recent target price actions are described explicitly: Deutsche Bank Research raised its target price from 102 EUR to 103 EUR on July 31, 2026, while Berenberg increased its target from 86 EUR to 94 EUR on July 29, 2026, with both houses maintaining a buy rating. The same analysis emphasizes that these upgraded targets sit well above the current share price, supporting the view that analysts consider the stock undervalued compared with their fundamental assessments.

The same report points out that Redcare Pharmacy shares are trading 36 percent below their 52-week high, while remaining 102 percent above the 52-week low. This dual comparison underlines a mixed picture for investors: the shares have more than doubled from their lowest level in the past year, yet they have given back a substantial portion of the earlier rally and now stand considerably below the peak that was reached during the prior 12 months. The quantified gap to the 52-week high provides a concrete signal of how much headroom analysts still see compared with recent trading levels.

Operational momentum: prescription volume jumps in Germany

The August 17, 2026 analysis also highlights an important operational development: Redcare Pharmacy has achieved a strong increase in prescription (Rx) volumes in Germany, with a reported 58 percent jump in this segment over a recent period. The report frames this 58 percent increase in German Rx sales as a key driver of the company’s growth story, especially as electronic prescriptions and online ordering gain traction among patients.

This 58 percent Rx growth figure is presented as part of the company’s latest available operating data, reflecting momentum in the core German business that is strategically important for Redcare Pharmacy. While the article does not include a full income statement, it connects the Rx surge to broader growth trends and suggests that prescription-driven revenue is expanding at a faster rate than some other segments. For investors, the clear quantified increase in Rx volume provides a concrete indicator of underlying demand and supports the thesis that the company is benefiting from structural changes in how healthcare customers obtain medications.

From a comparative perspective, a 58 percent increase in a key volume metric within a major market is substantial when measured against typical mid-single-digit or low-double-digit growth rates reported by many more mature healthcare and retail businesses. This magnitude suggests that Redcare Pharmacy is still in a scaling phase, with prescription volumes climbing rapidly as customers adopt online and digital tools for managing their treatments. The strong Rx trajectory helps explain why analyst targets sit well above the current share price despite the recent pullback from the 52-week high.

Market context and potential read-through from peers

A broader look at the European market environment indicates that major equity indices have recently reached record territory, with commentators stating on August 17, 2026 that they see limited risk of imminent sharp corrections in the absence of major geopolitical shocks. One weekly outlook discusses how the DAX index has rallied strongly and highlights several company-specific events that could shape individual share prices.

In that same outlook, the author notes that the upcoming half-year report from online pharmacy peer DocMorris may influence sentiment in the sector and could also move Redcare Pharmacy’s share price. The explicit mention of Redcare Pharmacy alongside DocMorris in a sector piece reminds investors that these companies often trade in relation to each other when new information on margins, growth rates, or regulation is released for one of the leading players. Even if Redcare Pharmacy is not itself reporting earnings on that day, an unexpectedly strong or weak half-year result from DocMorris can alter market expectations for Redcare’s revenue trajectory, profitability, or competitive position, potentially affecting valuation multiples applied to Redcare Pharmacy stock.

The sector backdrop is therefore relevant to the current situation: Redcare Pharmacy shares are trading well below their 52-week high at a time when analysts are raising targets and when investors expect upcoming data from a close competitor to provide fresh signals about demand, pricing, and regulatory developments in the online pharmacy space. The combination of index strength, sector-specific catalysts, and developing peer news contributes to the environment in which Redcare Pharmacy stock is currently valued and traded.

Fundamentals and guidance: what the latest data show

Recent financial portal data indicate that Redcare Pharmacy’s latest official company release was published on May 6, 2026, relating to a period with revenues reported at 849.5 million EUR. A company profile and results overview lists this 849.5 million EUR revenue figure as part of the most recent results release, although the detailed profit and earnings per share figures are not displayed in the snippet.

Because this May 6, 2026 release relates to a reporting period ending well within the last nine months before August 17, 2026, the revenue figure of 849.5 million EUR still falls inside the window for current fundamentals. Investors can therefore treat this revenue level as a recent snapshot of the company’s scale, while awaiting the next half-year or quarterly update for more granular data on margins and profitability. The reported revenue offers a concrete context for assessing valuation: when compared with the company’s market capitalization, investors can estimate forward-looking price-to-sales multiples and judge whether the stock trades at a premium or discount to peers.

The same portal indicates that earnings-per-share expectations were not prominently disclosed alongside this revenue figure in the snippet, suggesting that either consensus EPS data is limited or that the specific presentation focuses on sales rather than profit metrics. Still, the combination of strong revenue, a notable 58 percent Rx volume increase in Germany, and a trading price that stands 36 percent below the 52-week high forms a coherent picture of a growth company whose stock has recently consolidated after a substantial rally, while analysts remain comfortable raising their target prices.

Valuation metrics and quantified comparisons

The earlier mentioned German-language analysis places the recent closing price at 60.60 EUR on a prior trading day, with the stock standing 36 percent below the 52-week high and 102 percent above the 52-week low. That means if the 52-week low is taken as 100 percent of its value, the current share price has more than doubled from that trough, yet still sits more than one-third under the peak level achieved in the same period. This dual comparison gives investors a nuanced view: the stock has improved markedly from its weakest point but remains far from the highest valuations previously assigned by the market.

Comparing this closing price with the average target price of 61.00 EUR reported in the analyst consensus overview shows that the stock is trading only slightly below the average target, but significantly below the most bullish targets in the low-100 EUR range. In numerical terms, the difference between 60.60 EUR and the 61.00 EUR average target is modest, whereas the gap between 60.60 EUR and targets such as 94 EUR or 103 EUR represents a potential upside of more than 50 percent in the most optimistic scenarios. This spread between current market price, average target, and highest target helps quantify the degree of analyst conviction versus the current level of investor skepticism or caution.

More broadly, these comparisons suggest that while the market has reset expectations after a strong run that produced a 52-week high far above the low, sell-side analysts still project further gains based on their revenue growth assumptions and operating metrics such as the 58 percent Rx volume increase in Germany. For investors, the question is whether the current discount to the most aggressive targets compensates for the risks inherent in the competitive online pharmacy market and in potential regulatory changes affecting digital prescriptions and reimbursement.

Representative product: online prescription fulfilment service

A representative product in Redcare Pharmacy’s offering is its online prescription fulfilment service for customers in Germany, which allows patients to submit electronic prescriptions and have medication delivered directly to their homes. This service integrates with national e-prescription infrastructure and aims to reduce friction for chronic patients who require regular medication refills, presenting a convenient alternative to traditional brick-and-mortar pharmacies without sacrificing regulatory compliance or pharmacist oversight.

The strong 58 percent increase in prescription volumes reported in recent coverage can be linked to the growing adoption of this online prescription fulfilment service. As more physicians issue electronic prescriptions and more patients become comfortable managing their treatments through digital channels, the service’s usage naturally rises. For Redcare Pharmacy, this product not only drives revenue through medication sales but also creates opportunities to cross-sell related health products, loyalty programs, and digital services that support medication adherence and holistic healthcare management.

Redcare Pharmacy stock and recent trading levels

With the latest closing price cited at 60.60 EUR on a recent trading day and the stock trading 36 percent below its 52-week high while remaining 102 percent above its 52-week low, Redcare Pharmacy stock currently reflects both the gains of the past year and a meaningful retracement from peak levels. As of August 17, 2026, this positioning relative to the 52-week range, combined with an average analyst target price of 61.00 EUR and individual targets up to 103 EUR, frames the investment debate around whether the current discount to high-end estimates offers sufficient compensation for the operational and regulatory risks facing the online pharmacy sector.

Fact box

Company: Redcare Pharmacy N.V.
ISIN: NL0012044747
Ticker: RDC
Exchange: Cboe Europe (primary European trading venue)
Price (as of August 14, 2026, 11:30 a.m. EDT): 61.42 EUR
Market cap: 1.45 billion EUR (as of August 17, 2026)
Sector / Industry: Healthcare - Online pharmacy and e-commerce
Index membership: DAX